Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus.

Turnstone Biologics Inc. will receive upfront and near-term milestone payments and an equity investment totaling $120 million. President and CEO Sammy Farah said the investment will be part of a financing round...